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ARTICLE
Genetic Basis for Correction of Very-Long-Chain Acyl–Coenzyme
A Dehydrogenase Deficiency by Bezafibrate in Patient Fibroblasts:
Toward a Genotype-Based Therapy
S. Gobin-Limballe,* F. Djouadi,* F. Aubey, S. Olpin, B. S. Andresen, S. Yamaguchi, H. Mandel,
T. Fukao, J. P. N. Ruiter, R. J. A. Wanders, R. McAndrew, J. J. Kim, and J. Bastin
Very-long-chain acyl–coenzyme A dehydrogenase (VLCAD) deficiency is an inborn mitochondrial fatty-acid b-oxidation
(FAO) defect associated with a broad mutational spectrum, with phenotypes ranging from fatal cardiopathy in infancy
to adolescent-onset myopathy, and for which there is no established treatment. Recent data suggest that bezafibrate
could improve the FAO capacities in b-oxidation–deficient cells, by enhancing the residual level of mutant enzyme
activity via gene-expression stimulation. Since VLCAD-deficient patients frequently harbor missense mutations with
unpredictable effects on enzyme activity, we investigated the response to bezafibrate as a function of genotype in 33
VLCAD-deficient fibroblasts representing 45 different mutations. Treatment with bezafibrate (400 mM for 48 h) resulted
in a marked increase in FAO capacities, often leading to restoration of normal values, for 21 genotypes that mainly
corresponded to patients with the myopathic phenotype. In contrast, bezafibrate induced no changes in FAO for 11
genotypes corresponding to severe neonatal or infantile phenotypes. This pattern of response was not due to differential
inductions of VLCAD messenger RNA, as shown by quantitative real-time polymerase chain reaction, but reflected variable
increases in measured VLCAD residual enzyme activity in response to bezafibrate. Genotype cross-analysis allowed the
identification of alleles carrying missense mutations, which could account for these different pharmacological profiles
and, on this basis, led to the characterization of 9 mild and 11 severe missense mutations. Altogether, the responses to
bezafibrate reflected the severity of the metabolic blockage in various genotypes, which appeared to be correlated with
the phenotype, thus providing a new approach for analysis of genetic heterogeneity. Finally, this study emphasizes the
potential of bezafibrate, a widely prescribed hypolipidemic drug, for the correction of VLCAD deficiency and exemplifies
the integration of molecular information in a therapeutic strategy.
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Very-long-chain acyl–coenzyme A (CoA) dehydrogenase
(VLCAD) deficiency (MIM 609575) is an autosomal re-
cessive genetic disorder first identified in 19931 and now
considered one of the more common mitochondrial b-
oxidation disorders,2 with an estimated incidence of 1 in
30,000 to 1 in 120,000 births.3,4 The associated disease is
clinically heterogeneous in terms of age at onset, severity,
and affected tissues, but three main phenotypes have been
described.5 The most severe form of VLCAD deficiency
presents with neonatal cardiomyopathy and hepatic fail-
ure and is generally fatal in the 1st year of life. An infantile
presentation, mainly characterized by episodes of hypo-
ketotic hypoglycemia in early childhood, has also been
described. Finally, the most common phenotype is an ad-
olescent- or adult-onset myopathy with myalgia, cramps,
and exercise intolerance, with associated rhabdomyoly-
sis.2 This phenotype complexity suggests that different
therapeutic approaches will be necessary for appropriate
management of this disease; however, there is yet no es-
tablished therapy for VLCAD deficiency. Current man-
agement is largely supportive and is based on the admin-
istration of a high-carbohydrate, low long-chain fat diet
supplemented with medium-chain triglycerides. Because
of the severity of the symptoms and because life-threat-
ening manifestations can occur even in otherwise mild
phenotypes,6 newborn screening of VLCAD deficiency
has been implemented in most U.S. states, Australia, and
some European countries.4 Characterization of abnormal
plasma acylcarnitines by tandem mass spectrometry al-
lows the detection of suspected deficiency in newborns,
and definitive diagnosis is based on fatty-acid oxidation
(FAO) studies in fibroblasts or lymphocytes and/or se-
quence analysis of the VLCAD gene.3,4 The majority of
patients identified by neonatal screening are asymptom-
atic at diagnosis and are treated prospectively with pre-
ventive dietary measures, contributing to a decrease in
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disease mortality. However, these patients appear to fre-
quently develop muscular manifestations of the disease,
but the likelihood of illness and the long-term outcome
are so far not widely documented.
The diversity of disease presentations is clearly associ-
ated with a high genetic heterogeneity; however, the ge-
notype-phenotype correlations are not completely un-
derstood. More than 80 mutations, spread throughout the
20 exons of the VLCAD gene (17p13), have been reported,
and none of them are prevalent.2 The most-severe disease
presentations are often associated with null-type muta-
tions (i.e., large deletions and truncating, nonsense, or
splice mutations), which prevent the formation of any
functional protein and can account for the severity of the
associated phenotypes.2,5 However, these null mutations
represent only one-third of disease-associated sequence
variations, and the majority of patients harbor missense
mutations with potentially variable effects, and these can
be found in all three phenotypes.5,7 With the exception
of a few mutations that target the catalytic sites, predic-
tions of the effects of missense mutations are often un-
certain and require experimental studies. Functional anal-
ysis of mutations by cDNA expression studies have been
performed in a limited number of cases but could not
practically be extended to the spectrum of mutations al-
ready known in this disease. Biochemical studies of pa-
tient cells might provide an alternative for analysis of the
disease variability. In many cases, however, measurements
of FAO capacities or residual VLCAD enzyme activity, as
well as studies of acylcarnitine profiles in the patient cells,
do not reliably discriminate among the various forms of
the disease8 and do not clearly correlate with the various
genotypes.5 Thus, despite marked advances in diagnosis
and molecular characterization of the disease, the rela-
tions among the genotype variability, the severity of the
metabolic block, and the different possible phenotypes
are poorly understood in many VLCAD-deficient patients.
This obviously limits molecular-based predictions regard-
ing the evolution of the disease or the optimal case man-
agement, especially in the case of asymptomatic new-
borns, in which the molecular diagnosis remains, for these
reasons, of limited prognostic value.
In several genetic disorders, functional analysis of mu-
tations has proven to be essential not only for diagnosis
but also for the design of adapted therapeutic approaches.
For example, the pharmacological rescue of mutant pro-
teins that are misfolded, that exhibit abnormal cell traf-
ficking, or that are constitutively activated is now consid-
ered a possible option for the correction of various genetic
diseases, including cystic fibrosis, Pompe disease, or neo-
natal diabetes, illustrating that a combined pharmacolog-
ical and genetic approach can offer the prospect of tar-
geting genotype-specific therapies.9–12 In a recent study,
we established that pharmacological enhancement of a
deficient enzyme could be achieved in cells carrying mild
mutations of the CPT2 (carnitine palmitoyl transferase 2)
gene, and this could lead to the normalization of FAO
capacities.13,14 This was achieved through cell exposure to
bezafibrate, a drug widely used for its hypolipidemic ac-
tion15 and acting as an agonist of the peroxisomal proli-
ferator-activated receptors (PPARs). Upon pharmacologi-
cal activation, PPARs trigger an up-regulation of CPT2 gene
expression, which results in an increase in CPT2 residual
enzyme activity and thereby correction of FAO flux in
treated cells. This approach can conceivably be extended
to other FAO defects, since the PPAR signaling pathway
controls many different enzymes in the b-oxidation path-
way. In keeping with this hypothesis, a pilot study estab-
lished a beneficial effect of bezafibrate in a small series of
VLCAD-deficient fibroblasts.16 However, as for the correc-
tion of other genetic diseases on the basis of a similar
strategy, it can be anticipated that the drug effects will
closely depend on the ability to produce a partially active
mutant protein. Since most VLCAD-deficient patients
harbor mutations with variable and unpredictable effects
on the enzyme properties,7 the potential of bezafibrate for
correction of VLCAD deficiency cannot be anticipated
from the nature of these mutations, and it appeared es-
sential to analyze the responsiveness to the drug in rela-
tion to the genotype variability. On this basis, we inves-
tigated the effects of bezafibrate on FAO capacities in a
large and genetically heterogeneous panel of VLCAD-de-
ficient cells and focused in particular on the study of ge-
notypes carrying missense mutations.
We hypothesized that this pharmacological approach
could provide a way to compare the functional conse-
quences of various genotypes, or of various mutations, on
the cell metabolic capacities. The other objective of this
study was to characterize the nature and the proportion
of VLCAD-deficient genotypes on which bezafibrate could
have beneficial effects—that is, could improve or correct
the defect in FAO capacity—in a relatively large sample
of patient cells.
Subjects and Methods
Patients and Control Cells
VLCAD-deficient human skin fibroblasts were obtained with con-
sent from different reference centers for the diagnosis of inborn
metabolic diseases. All cell lines had been previously genotyped:
their genotypes are given with references in table 1 and are po-
sitioned along the VLCAD gene in figure 1. The case histories of
some of the patients included in this study have been published
previously.5,16–27 An indication of the phenotype at the time of
diagnosis is included in table 1. The neonatal (N) phenotype pre-
sented with cardiomyopathy, often in association with liver fail-
ure, possibly resulting in death within the 1st year of life. The
infantile (I) form was characterized by liver failure with hypok-
etotic hypoglycemia, without heart or muscle involvement. Fi-
nally, the myopathic (M) phenotype included patients with met-
abolic myopathy (i.e., myalgia, exercise intolerance, and rhabdo-
myolysis) generally of adolescent or adult onset, except for ge-
notypes 5, 12, 18, and 25, in which muscular manifestations de-
veloped earlier (before age 8 years). Control fibroblast cell lines
were from healthy individuals.
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Table 1. Genotypes of the VLCAD-Deficient Patients
Genotype
Allele 1 Allele 2
Phenotypec Reference(s)dNucleotide Changea Exon(s)
Amino Acid
Changeb Nucleotide Changea Exon(s)
Amino Acid
Changeb
1 c.37CrT 1 Q13X c.856ArG 9 R286G N …
2 c.102delC 2 G34fsX60 c.102delC 2 G34fsX60 N Andresen et al.5
3 c.194CrTc.739ArC 3 and 8 P65LK247Q c.194CrTc.739ArC 3 and 8 P65LK247Q N Watanabe et al.27
4 c.265CrT 4 P89S c.1606_1609del 17 A536fsX550 I* Takusa et al.25
5 c.272CrA 4 P91Q c.577GrA 7 G193R M* Engbers et al.19
6 c.364ArG 6 N122D c.364ArG 6 N122D I Djouadi et al.16
7 c.388_391del 6 E130fsX216 c.1144ArC 11 K382Q (7) N Aoyama et al.18
8 c.442ArG 6 S148G c.1531CrT 15 R511W M …
9 c.520GrA 7 V174M c.520GrA 7 V174M M Djouadi et al.16
10 c.553GrA 7 G185S (1) IVS8-2ArC 9 N252_H293del (3) N Andresen et al.,5
Pons et al.22
11 c.553GrA 7 G185S (1) c.878GrA 10 G294E I* Andresen et al.5
12 c.664GrA 8 G222R (2) c.664GrA 8 G222R (2) M* …
13 c.664GrA 8 G222R (2) c.1512GrT 15 E504D M …
14 c.685CrT 8 R229X c.1837CrT 20 R613W N …
15 IVS8-2ArC 9 N252_H293del (3) c.1322GrA 13 G441D (9) N Andresen et al.,17
Pons et al.22
16 c.779CrT 9 T260M c.1918_1921del 20 A640fsX679 N Andresen et al.17
17 c.790ArG 9 K264E (4) c.790ArG 9 K264E (4) M Takusa et al.25
18 c.790ArG 9 K264E (4) c.997insT 10 A333fsX358 (6) M* Takusa et al.25
19 c.790ArG 9 K264E (4) c.1309ArG 13 M437V M Takusa et al.25
20 c.848TrC 9 V283A (5) c.848TrC 9 V283A (5) M Djouadi et al.16
21 c.848TrC 9 V283A (5) c.1322GrA 13 G441D (9) M Andresen et al.5,17
22 c.848TrC 9 V283A (5) c.1384GrA 14 E462K M Andresen et al.5
23 c.896CrT 10 K299M c.1505TrA 15 L502Q M Tong et al.26
24 c.910GrA 10 A304T c.1316GrA 12 G439D M …
25 c.997insT 10 A333fsX358 (6) c.1144ArC 11 K382Q (7) M* …
26 c.1097GrA 11 R366H c.1358GrT 14 R453X M Andresen et al.5
27 c.1144ArC 11 K382Q (7) c.1339GrA 14 G447R M Souri et al.24
28 c.1213GrC 12 D405H c.1349GrA 14 R450H (10) M Smelt et al.23
29 c.1246GrA 12 A416T (8) c.1349GrA 14 R450H (10) M Fukao et al.20
30 c.1246GrA 12 A416T (8) c.1798delA 19 K600fsX679 M Takusa et al.25
31 c.1358GrA 14 R453Q c.1358GrA 14 R453Q N Andresen et al.5
32 c.1367GrA 14 R456H c.1844GrA 20 R615Q M Andresen et al.,5
Mathur et al.21
33 c.1405CrT 14 R469W c.1405CrT 14 R469W N Andresen et al.5
a The numbering of nucleotides starts at the first adenine of the translation initiation codon.
b The numbering of amino acids starts at the first methionine encoded by the translation initiation codon. Numbers 1–9 (in parentheses) indicate the genotypes that
have this mutation in common.
c Phenotype at the time of diagnosis. I p infantile; M p muscular; N p neonatal. An asterisk (*) indicates moderate infantile or severe muscular forms.
d References describing the genotype or only one of the two mutations.
Cell Culture
Fibroblasts from normal or VLCAD-deficient cells were grown in
Ham’s F10 media (Invitrogen) with glutamine, 12% fetal bovine
serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin under
standard conditions, as described elsewhere.16 For treatment, cells
were incubated in fresh media containing 400 mM bezafibrate
(Sigma) or the equivalent amount of dimethyl sulfoxide (vehicle)
for 48 h.
FAO
FAO flux was determined by quantifying the production of 3H2O
from (9,10-3H) palmitate (Perkin Elmer), as described elsewhere.28
Palmitate bound to fatty-acid–free albumin was used at the final
concentration of 125 mM (60 Ci/mmol). The oxidation rates were
expressed as nanomoles of 3H fatty acid oxidized per hour per
milligram of cell protein (nmol 3H FA/h/mg protein).
Enzyme Activity
VLCAD activity was measured as 2,3-unsaturated-palmitoyl-
CoA and b-hydroxypalmitoyl-CoA formed from palmitoyl-CoA
by high-performance liquid chromatography, as described else-
where.29 It was expressed as nanomoles of 2,3-unsaturated-pal-
mitoyl-CoA formed per minute per milligram of cell protein
(nmol/min/mg protein).
Real-Time Quantitative PCR
Total RNA from controls or VLCAD-deficient patients was isolated
using Trizol reagent (Invitrogen) and was transcribed into cDNA.
VLCAD and b-actin transcripts were amplified with primers de-
scribed elsewhere16 and were measured by real-time quantitative
PCR by use of the SYBR Green technology kit (Abgene) and the
LightCycler instrument (Roche). The results are expressed in ar-
bitrary units as fold changes in VLCAD mRNA levels, normalized
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Figure 1. Schematic representation of the different genotypes along the VLCAD gene. Homozygous genotypes are indicated by a single
triangle, and heterozygous genotypes are indicated by two triangles linked by a dashed line. One homozygous double point mutation
(P65LK247Q) is indicated by triangles linked by a continuous line. A, Genotypes with no mutation in common. B, Genotypes with
mutations in common. The common mutations are indicated by dark triangles.
to the amount of b-actin, in treated cells relative to untreated
ones.
Protein Sequence Analysis
Human and rat VLCAD (GenBank accession numbers P49748
and P45953, respectively), human, pig, and rat medium-chain
acyl-CoA dehydrogenase (MCAD [GenBank accession numbers
P11310, P41367, and P08503, respectively]), and human and rat
short-chain acyl-CoA dehydrogenase (SCAD [GenBank accession
numbers P16219 and P15651, respectively]) protein sequences
were aligned using the online Multi-Align Tool, to identify con-
served residues.
Predictive Three-Dimensional Model
The crystal structure of the VLCAD protein has not yet been
elucidated, and the proposed three-dimensional model of VLCAD
is derived from the established MCAD model.30 Amino acid se-
quence homology between VLCAD and MCAD is 33% for residues
77–480 of VLCAD, indicating that the N-terminal domains of
both enzymes are very similar. The structure of this N-terminal
VLCAD domain (residues K79–K480) was modeled with the com-
parative protein structure modeling program, MODELLER,31 with
use of the structure of MCAD in complex with octanoyl-CoA
(Protein Data Bank code 3MDE) as a template. The structure of
the 180-residue C-terminal domain of VLCAD anchored to the
mitochondrial membrane, which is absent from MCAD, is pres-
ently unknown.
Results
Effects of Bezafibrate on FAO Capacities in VLCAD-
Deficient Fibroblasts: Can the Response to Bezafibrate Reveal
the Residual FAO Capacities of a Given Genotype?
Determinations of basal palmitate oxidation rates in un-
treated cultured fibroblasts (fig. 2) revealed that most pa-
tient cell lines exhibited a significant deficiency in long-
chain FAO capacities, compared with the control values
(4.81.0 nmol 3H FA/h/mg protein; ). Indeed, onlynp 5
4 of the 33 cell lines (genotypes 13, 17, 32, and 21) ex-
hibited FAO rates (3.7–4.5 nmol 3H FA/h/mg protein)
close to the control range. In the other 29 cell lines, the
FAO rates varied from an upper value of 3 nmol 3H FA/h/
mg protein (genotype 19, 38% relative to mean control
value) to barely detectable levels (genotypes 3, 10, and 14,
complete FAO deficiency). Overall, the FAO-deficient ge-
notypes included 18 cell lines with residual FAO capaci-
ties of 0–1 nmol 3H FA/h/mg protein (FAO deficiency
180% compared with control), 9 cell lines with FAO rates
of 1–2 nmol 3H FA/h/mg protein (relative FAO deficiency
from58% to80%), and 2 cell lines with a residual FAO
flux of 2–3 nmol 3H FA/h/mg protein (FAO deficiency
from 58% to 38%), in the absence of treatment with
bezafibrate.
Addition of 400 mM bezafibrate for 48 h to the cultured
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Figure 2. b-oxidation flux measured in fibroblasts of control and VLCAD-deficient patients before (gray square) and after (blackened
rhombus) treatment with bezafibrate (400 mM for 48 h). In each experiment, the assays were performed in triplicate. The results are
meansSDs from at least three different experiments. For control values, five different healthy individuals were considered. The control
ranges (untreated cells) represented by the horizontal lines are the SD and the SD of the five controls. Eachmean 1 mean 1
genotype is numbered as in table 1.
fibroblasts induced major changes in the FAO capacities
in about two-thirds (21 of 33) of the cell lines considered.
These effects of bezafibrate on FAO are depicted in figure
2, in which the various genotypes were ranked according
to the level of palmitate oxidation reached after cell ex-
posure to the drug, revealing the maximal residual FAO
capacities of each cell line. Analysis of the FAO data clearly
identified three groups. In the first group ( ), beza-np 12
fibrate induced no significant changes in FAO capacities,
which remained extremely low compared with normal
(!1.5 nmol 3H FA/h/mg protein). The second group in-
cluded seven cell lines in which bezafibrate induced a sig-
nificant (1.5- to 3.5-fold) increase in palmitate oxidation
but did not fully restore FAO capacities. Indeed, bezafi-
brate-treated group 2 cells exhibited palmitate oxidation
rates varying from 1.5 to 3.3 nmol 3H FA/h/mg protein
compared with a control range of 3.8–5.8 nmol 3H FA/h/
mg protein (untreated cells). Finally, the third group com-
prised 14 VLCAD-deficient cells, in which bezafibrate in-
duced full restoration of palmitate oxidation. Of these 14
cell lines, 10 were initially deficient compared with con-
trol fibroblasts. The results obtained in this group showed
that treatment with bezafibrate could, at least in some
cases, correct major FAO deficiencies such as those found
in untreated cells of genotypes 22, 27, 25, or 9 (from75%
to 65% relative to control).
Fibroblast Response to Bezafibrate in Relation to the Disease
Phenotype
Analysis of FAO results in relation to patient phenotypes
showed that 11 (190%) of the 12 group 1 cell lines that
did not respond to bezafibrate came from patients with a
severe (neonatal or infantile) presentation of the disease.
The only patient with a myopathic phenotype found in
group 1 (genotype 12) presented severe muscular mani-
festations early in life, corresponding to an aggravated my-
opathic phenotype. On the other hand, 19 (190%) of 21
cell lines in which bezafibrate induced a significant in-
crease in FAO (groups 2 and 3) originated from patients
with the myopathic phenotype.
Changes in VLCAD mRNA Abundance in Cells Treated
with Bezafibrate
The results from real-time quantitative PCR studies re-
ported in figure 3 showed that exposure to bezafibrate
generally induced significant increases in VLCAD mRNA
levels in the various cell lines. Interestingly, the changes
in VLCAD mRNA triggered by bezafibrate were equivalent
in the group 1 (from 1.2-fold to 2.1-fold), group 2 (from
1.2-fold to 2.5-fold), and group 3 (from 1.3-fold to 2.3-
fold) genotypes. Furthermore, these variations were quite
comparable with those measured in control fibroblasts
( ), in which VLCAD mRNA increased by a factor ofnp 4
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Figure 3. Induction of VLCAD mRNA by bezafibrate. The results are expressed as the percentage increase relative to vehicle-treated
cells.
1.3–2 after treatment with bezafibrate. Only one cell line
(genotype 2, group 1) exhibited extremely low basal
VLCAD mRNA levels that did not vary in response to be-
zafibrate, consistent with the fact that the corresponding
mutations cause mRNA degradation by the nonsense-me-
diated mRNA decay system.7
Induction of VLCAD Activity in Drug-Treated Cells
Enzyme activity determinations showed that untreated
VLCAD-deficient fibroblasts from group 1 exhibited no or
barely detectable residual VLCAD activity (fig. 4). The
basal levels observed in groups 2 and 3, which ranged
from 0.4 to 3.3 nmol/min/mg protein, were slightly
higher than those in group 1 but still remain markedly
deficient compared with the values found in control fi-
broblasts (111.9 nmol/min/mg protein; ). Figure 4np 3
shows that the stimulation of the residual enzyme activity
of VLCAD by bezafibrate in group 3 ranged from 2.2- to
4.8-fold compared with the values in untreated cells. The
levels of VLCAD enzyme activities in the bezafibrate-
treated group 3 fibroblasts were close to normal in two
cases (7.1 and 8.9 nmol/min/mg protein in genotypes 20
and 17, respectively) but generally remained deficient in
all the other cell lines, despite the induction triggered by
bezafibrate.
Altogether, VLCAD mRNA levels were induced in the
large majority of patient fibroblasts treated with bezafi-
brate, irrespective of the nature of the point mutation(s).
In contrast, the response to drug treatment in terms of
changes in FAO capacities markedly differed among the
various genotypes. In the genotypes classified as group 3,
drug-induced increases in VLCAD mRNA clearly led to a
stimulation of residual enzyme activity that accounted for
the restoration of palmitate oxidation rates. In contrast,
in genotypes that were ranked in group 1, increases in the
steady-state level of VLCAD mRNA did not translate into
a stimulation of FAO capacities because of the absence of
changes in VLCAD residual activity, which remained ex-
tremely low despite treatment with bezafibrate. Conse-
quently, these responses to bezafibrate led us to classify
the various genotypes as “mild” (groups 2 and 3) or “se-
vere” (group 1). We then analyzed these data to determine
whether contributions of individual mutant alleles to the
response to bezafibrate could be identified.
Cross-Analysis of Genotypes: Can the Response
to Bezafibrate Predict the Severity of VLCAD Gene Point
Mutations?
Group 1 includes four homozygous genotypes with point
mutations N122D (genotype 6), G222R (genotype 12),
R453Q (genotype 31), and R469W (genotype 33) and five
heterozygous genotypes with a null mutation on one al-
lele (nonsense, deletion, or frameshift leading to a pre-
mature stop codon) associated with one of the following
point mutations on the other allele: G185S (genotype
10), T260M (genotype 16), R286G (genotype 1), G441D
(genotype 15), or R613W (genotype 14). These genotypes
identify nine distinct amino acid substitutions in the
VLCAD protein sequence that lead to extremely low re-
sidual capacities and therefore seriously affect the activity
and/or the stability of the mutant protein. In keeping with
this, studies in cells of genotypes 6, 12, and 1 revealed
undetectable VLCAD enzyme activities after treatment
with bezafibrate. Genotype 11 (G185S/G294E) is the only
compound heterozygous genotype in group 1; it included
the severe G185S substitution already found in association
with a null mutation (genotype 10, group 1). This indi-
cates that expression of the allele carrying the G294E sub-
stitution cannot compensate for the effects of the G185S
mutation and, consequently, that G294E is also a severe
mutation.
Genotypes ranked in group 3 demonstrated a good re-
sponse to bezafibrate, resulting in the restoration of FAO
rates to control values even though most of these cell lines
exhibited a significant FAO deficiency before treatment.
Three of these cell lines carried the homozygous point
mutations V174M (genotype 9), K264E (genotype 17),
and V283A (genotype 20), indicating that these muta-
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Figure 4. VLCAD activity measured in fibroblasts of VLCAD-deficient patients before (gray triangles) and after (black triangles) treatment
with bezafibrate (400 mM for 48 h). Each determination was performed in duplicate.
tions were relatively benign amino acid substitutions. The
V283A mutation was also found to be compound hetero-
zygous in two group 3 genotypes associated either with
G441D (genotype 21), a severe group 1 mutation, or with
E462K (genotype 22), a well-known severe mutation that
targets the catalytic residue of VLCAD.32 Interestingly, af-
ter treatment with bezafibrate, enzyme activity determi-
nations in fibroblasts from genotypes 20, 21, and 22 re-
vealed similar activity levels in genotypes 21 and 22,
which harbored one V283A allele, and about twice this
level in genotype 20, which was homozygous for this mu-
tation. This clearly suggests that the expression of a single
allele carrying the V283A mutation is sufficient to restore
normal FAO capacities in response to bezafibrate and can
compensate for a highly deleterious mutation on the other
allele. The K264E mutation present at a homozygous state
in genotype 17 was also found to be compound hetero-
zygous in genotypes 18 and 19. Interestingly, cells carrying
the mutation K264E in association with the null mutation
A333fsX358 (genotype 18, group 2) exhibited only a par-
tial response to drug treatment, suggesting that the ex-
pression of a single allele carrying the K264E substitution
leads to a variant enzyme that is functional but probably
less active and/or stable than that in the case of V283A.
On the other hand, the genotype K264E/M437V (geno-
type 19) exhibited FAO values that ranked among the
highest observed in group 3, suggesting that the M437V
allele could also contribute to the response to the drug
and might therefore represent a mild mutation. Finally,
as observed for V283A, a compensatory effect of a mild
mutation over a severe one was suggested in the case of
E504D. Indeed, genotype 13, associating E504D with the
severe mutation G222R, exhibited high basal and drug-
stimulated FAO rates, and enzyme levels measured in this
cell line were consistent with these observations, clearly
indicating that E504D alone can compensate for the pres-
ence of the severe G222R allele.
The genotypes 4, 26, and 30, carrying the missense mu-
tations P89S, R366H, and A416T, respectively, were seen
in combination with different null mutations. These three
cell lines clearly ranked in group 2, suggesting that the
P89S, R366H, or A416T substitutions, although relatively
mild, are not compatible with restoration of full FAO ca-
pacities after treatment with bezafibrate. Two cell lines
(genotypes 7 and 25 in groups 2 and 3, respectively) har-
bored the same substitution, K382Q, in combination with
two distinct null mutations. The drug-stimulated FAO lev-
els appeared slightly higher in genotype 25 compared
with genotype 7, but there was overlap between these two
cell lines, and these results clearly indicated that K382Q
can be considered a relatively mild amino acid substitu-
tion. Interestingly, genotype K382Q/G447R (genotype 27,
group 3) exhibited FAO rates quite similar to those found
in genotype 25, in which K382Q is associated with a null
allele. This suggests that the G447R substitution does not
contribute to a significant extent to the response to be-
zafibrate and could therefore represent a severe mutation.
Altogether, cross-analysis of these genotypes led to the
identification of a number of VLCAD mutant alleles that
could each account for the observed FAO increase in re-
sponse to bezafibrate. At the amino acid level, substitu-
tions identified as mild were P89S, V174M, K264E,
V283A, R366H, K382Q, A416T, M437V, and E504D. We
also identified the severe mutations N122D, G185S,
G222R, T260M, R286G, G294E, G441D, G447R, R453Q,
R469W, and R613W. Finally, for some compound heter-
ozygotes ranked in groups 2 or 3, analysis of our data
alone could not predict the possible contributions of
the individual alleles. This was the case for genotypes 5
(P91Q/G193R), 8 (S148G/R511W), 23 (K299M/L502Q), 24
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Figure 5. The dimeric structure of VLCAD shown with some hu-
man mutation sites. Each subunit is represented in light or dark
blue. The FAD cofactor and the substrate (C8-CoA) are shown with
sticks in yellow and pink, respectively. Mutation sites are shown
in both subunits. Mutations on the light-blue monomer are marked
with pink (severe) or dark-green (mild) balls, and those on the
dark-blue monomer are shown with red (severe) or light-green
(mild) balls. The C-terminal domain, which is unique only in VLCAD
and is not present in other acyl-CoA dehydrogenases, is depicted
as a gray blob anchored to the mitochondrial inner membrane.
(A304T/G439D), 28 (D405H/R450H), 29 (A416T/ R450H),
and 32 (R456H/R615Q).
The mutation classification based on the response to
bezafibrate was compared with functional data from the
literature, and some representative mutations were lo-
cated spatially on a three-dimensional model of the
VLCAD protein (fig. 5). To our knowledge, no functional
data are available for the severe point mutations identi-
fied in our experiments, with the exception of T260M,
R469W, and R613W, as well as the double point mutation
P65LK247Q, for which previous reports demonstrated a
complete absence or a very low residual VLCAD enzyme
activity, consistent with our observations.24,27,33 When
mapped on the three-dimensional VLCAD model (fig. 5),
a number of severe point mutations identified by our FAO
test pointed to amino acid residues essential for the ar-
chitecture of the active site (G185S), for flavin adenine
dinucleotide (FAD) binding (G222R, G441D, and R453Q),
or for protein stability (N122D, R286G, and G447R). In
the case of G185S, for example, the mutation involves a
residue immediately next to the conserved Ile184 lining
the substrate-binding cavity that accommodates the fatty
acyl moiety in the MCAD structure.30,34 The mutation
G222R involves the first residue of a conserved Gly-Ser-
Asp segment directly involved in the binding of FAD in
both MCAD and SCAD.30,34,35 Similarly, the mutation
G441D affects an amino acid that is part of a highly con-
served Gly-Gly-x-Gly motif close to the FAD binding
pocket.17 In the case of R453Q, a mutation of the equiv-
alent residue in SCAD (R359C) was shown to be disease
causing in humans, and cDNA expression studies of this
SCAD mutation suggested major protein-folding altera-
tions.36 Indeed, R453Q involves a highly conserved residue
located near the two-fold axis of the VLCAD dimer and
on one of the a-helices that form the FAD binding pocket
domain of the enzyme.
Concerning the mild mutations characterized in our
study, cDNA functional analysis of P89S, K264E, K382Q,
A416T, and M437V VLCAD mutants in human fibro-
blasts25 or Chinese hamster ovary cells24 showed that all
these variant proteins, though unstable, exhibited variable
levels of residual enzyme activity. Similarly, the mutant
V283A protein produced by cDNA expression in COS-7
cells exhibited significant residual activity, whose level ap-
peared proportional to the amount of mutated protein.5,
37 The mild mutations identified through the FAO studies
did not involve residues essential for enzyme catalysis, as
assessed from the three-dimensional VLCAD model.
Discussion
Patients with VLCAD deficiency can present quite variable
symptoms associated with a wide variety of gene muta-
tions, but the molecular basis of disease variability is
poorly understood. In particular, a large proportion of pa-
tients harbor gene missense mutations whose effects on
residual metabolic capacities are often unknown.5 The pre-
sent study shows that studying the pharmacological pro-
file of VLCAD-deficient cells can provide valuable infor-
mation in comparing the relative severity of various ge-
notypes or of missense mutations and, at the same time,
can provide a genetic basis for a therapeutic approach to
this disorder. Assays of palmitate oxidation revealed that
about two-thirds (63%) of the patient cell lines exhibited
a marked increase in their FAO capacities in response to
bezafibrate, whereas, in the remaining cell lines, drug
treatment was without effect. These differences could not
be explained by variable inductions of VLCAD gene ex-
pression by bezafibrate, since similar increases in VLCAD
mRNA levels were observed in all the treated cells, with
the exception of those carrying null mutations leading to
mRNA degradation (genotype 2). Interestingly, the lack of
response to bezafibrate in genotype 2, and in two other
cell lines carrying null mutations on both alleles (data not
shown), indicates that a possible induction by bezafibrate
of other b-oxidation enzymes, like the long-chain acyl-
CoA dehydrogenase or the recently described acyl-CoA
dehydrogenase 9,38 does not contribute to the FAO ca-
pacities in the treated VLCAD-deficient fibroblasts. In fact,
the pattern of FAO responses to bezafibrate appeared to
be mainly determined by the variable degree of increase
in VLCAD residual enzyme activity that resulted from the
treatment. It could therefore be envisaged that the FAO
values measured in drug-treated cells represent the end
result of the variable consequences of the mutations on
cell residual enzyme activity.
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This study consistently suggests that the various VLCAD
gene mutations are the main determinants to explain the
different responses to bezafibrate. In support of this, our
results showed a complete restoration of FAO capacities
in bezafibrate-treated cells carrying one or two copies of
the V283A mutant allele, in keeping with previous studies
showing that this mutant VLCAD enzyme retained a sig-
nificant residual enzyme activity.17,37 Conversely, negligi-
ble FAO rates were found in association with severe mu-
tations like R613W, which was previously shown to fully
abolish residual enzyme activity.24 Since VLCAD is a di-
meric enzyme, a functional complementation between
two monomers carrying distinct mutations could be en-
visaged. For example, a missense mutation targeting the
catalytic site might conceivably complement another mis-
sense mutation that does not affect catalysis but induces
protein instability. However, careful analysis of the en-
zymatic and FAO data obtained from our panel of geno-
types does not yield examples in support of this hypoth-
esis. Cross-analysis of genotypes with common missense
mutations always gave consistent pictures of the contri-
bution of individual mutant alleles to the response to be-
zafibrate. It should also be mentioned that similar FAO
responses were found when the effects of bezafibrate were
compared in fibroblasts from several siblings or in cells
from unrelated patients with identical genotypes (data not
shown). Altogether, the response to bezafibrate is directly
determined by the genotype.
In this regard, the results highlighted a first group of
genotypes with missense mutations affecting amino acid
positions often essential for enzyme catalysis, leading to
a collapse of FAO capacities with no response to bezafi-
brate. This analysis showed a striking correlation with the
presentation of the disease, since all the cells from patients
with a severe neonatal or infantile form of the disease were
finally classified in this group 1, which, in addition, in-
cluded one single cell line from a patient with a myopathic
phenotype but with an unusually severe presentation.
Conversely, the same approach led to identification of the
group 2 and group 3 genotypes, which exhibited a sig-
nificant response to bezafibrate, and all these cell lines
originated from patients with the myopathic disease phe-
notype. Analysis of the mild mutations in the three-di-
mensional model illustrated substitutions that generally
did not disrupt bonding arrays essential for enzyme ca-
talysis or quaternary structure but rather induced mis-
folded unstable proteins. Partial correction of FAO ob-
served in some cases (group 2) often corresponded to
genotypes with a missense mutation associated with a null
mutation on the other allele. We hypothesize that some
of these group 2 missense mutations might have generally
more-deleterious effects than those found in the group 3
genotypes. This is illustrated in the case of R366H (ge-
notype 26), which is predicted to weaken FAD binding
and is associated with a relatively low FAO response after
treatment with bezafibrate.
It can be concluded that measurements of FAO after
pharmacological stimulation by bezafibrate provide a sim-
ple functional assay to optimally compare the residual
metabolic capacities in a large panel of VLCAD-deficient
cells. This assay allowed the identification of drug-respon-
sive genotypes and, in some cases, drug-responsive indi-
vidual mutations in this panel of genotypes. Thus, the
correlation of pharmacological and genetic information
allows the characterization of the effects of bezafibrate as
a function of patient genotype. The FAO test in bezafi-
brate-treated cells also provides an index of the severity
of metabolic block, which appears well correlated to the
disease phenotype. This clearly suggests that the pheno-
typic variability is related to marked differences in the
residual capacities of the b-oxidation pathway and pro-
vides new insights into the genotype-phenotype correla-
tions in patients harboring missense mutations. We pro-
pose that this experimental approach could find valuable
applications to improve the diagnosis and to allow better
predictions of disease severity in relation to the genotype,
an issue particularly important for the management of
asymptomatic newborns.
Our results highlight the potential of bezafibrate to im-
prove or correct the long-chain FAO defect in the patient
cells. Indeed, treatment with bezafibrate significantly im-
proved the FAO capacities in all the cells coming from
patients with a typical myopathic form of the disease and
restored normal FAO rates in the majority of these cell
lines. So far, therapeutic approaches are extremely limited
in this disease, as in many other FAO disorders.8 The re-
sults obtained in the present study provide grounds for
future clinical studies of a possible correction of VLCAD
deficiency by bezafibrate, a drug that has been prescribed
for 125 years with a good safety profile,15 or for the use
of some related compounds like new-generation PPAR ag-
onists. The responsiveness to these drugs in relation to the
genotype, which can be simply addressed in patient fi-
broblasts, provides a rationale to select responder geno-
types, which could be used for the stratification of patients
in future clinical trials. Finally, this study points out that,
despite the great diversity of possible consequences of mis-
sense mutations for enzyme synthesis, activity, or steady-
state level,7 the pharmacological stimulation of mutant
VLCAD gene expression turned out to improve or correct
the b-oxidation capacities in a relatively large panel of
genotypes. Altogether, integration of molecular informa-
tion in a therapeutic strategy could find fruitful applica-
tions to develop new treatments adapted not only to spe-
cific mutations but also to a broad spectrum of genotypes.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for protein
sequences of human [accession number P49748] and rat [ac-
cession number P45953] VLCAD; human [accession number
P11310], pig [accession number P41367] and rat [accession
number P08503] MCAD; and human [accession number
P16219] and rat [accession number P15651] SCAD)
Multi-Align Tool, http://searchlauncher.bcm.tmc.edu/multi-align/
multi-align.html
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for VLCAD deficiency)
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